Screener
Acadia Pharmaceuticals ACAD Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 81,555 | 77,951 | 158,423 | 156,216 |
| Selling, general and administrative | 160,252 | 133,507 | 331,271 | 259,877 |
| Total operating expenses | 270,123 | 232,192 | 542,801 | 457,219 |
| Income from operations | 37,836 | 32,374 | 33,220 | 51,663 |
| Interest income, net | 7,990 | 7,243 | 16,045 | 15,144 |
| Other income | 647 | 594 | 1,189 | 1,183 |
| Income before income taxes | 46,473 | 40,211 | 50,454 | 67,990 |
| Income tax expense | 14,973 | 13,545 | 15,317 | 22,337 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's operating income?
- Acadia Pharmaceuticals (ACAD) reported operating income of $37.84M in Q2 2026.
- How has Acadia Pharmaceuticals's operating income changed year-over-year?
- Acadia Pharmaceuticals's operating income increased by 16.9% year-over-year, from $32.37M to $37.84M.
- What is the long-term trend for Acadia Pharmaceuticals's operating income?
- Over 3 years (2021 to 2025), Acadia Pharmaceuticals's operating income has grown at a -15.0% compound annual growth rate (CAGR), from -$170.44M to $104.81M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Acadia Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude